Tectonic Advisors LLC Purchases 792 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tectonic Advisors LLC increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,439 shares of the medical equipment provider’s stock after acquiring an additional 792 shares during the quarter. Tectonic Advisors LLC’s holdings in Zimmer Biomet were worth $469,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dunhill Financial LLC raised its position in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet during the 3rd quarter worth approximately $28,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the third quarter valued at approximately $35,000. R Squared Ltd bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $63,000. Finally, Mather Group LLC. raised its holdings in shares of Zimmer Biomet by 100.9% during the fourth quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock worth $70,000 after acquiring an additional 332 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZBH has been the subject of a number of research reports. Oppenheimer lowered their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Truist Financial increased their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, January 29th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $102.84 on Friday. The firm has a market cap of $20.47 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a one year low of $100.67 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The stock’s fifty day moving average price is $107.75 and its two-hundred day moving average price is $108.20.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same quarter in the previous year, the business earned $2.20 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.93%. Zimmer Biomet’s payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.